WO2006033081A3 - Peroxisome proliferation receptor agonists, for the treatment of gastritis - Google Patents

Peroxisome proliferation receptor agonists, for the treatment of gastritis Download PDF

Info

Publication number
WO2006033081A3
WO2006033081A3 PCT/IB2005/053121 IB2005053121W WO2006033081A3 WO 2006033081 A3 WO2006033081 A3 WO 2006033081A3 IB 2005053121 W IB2005053121 W IB 2005053121W WO 2006033081 A3 WO2006033081 A3 WO 2006033081A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
gastritis
receptor agonists
gamma
peroxisome proliferation
Prior art date
Application number
PCT/IB2005/053121
Other languages
French (fr)
Other versions
WO2006033081A2 (en
Inventor
Antonio Soleti
Gianfranco Merizzi
Original Assignee
Medestea Res & Production S P
Antonio Soleti
Gianfranco Merizzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Res & Production S P, Antonio Soleti, Gianfranco Merizzi filed Critical Medestea Res & Production S P
Publication of WO2006033081A2 publication Critical patent/WO2006033081A2/en
Publication of WO2006033081A3 publication Critical patent/WO2006033081A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to selective agonists or ligands of the peroxisome proliferator-activated receptors alpha and gamma (PPAR alpha and gamma) and their use for the manufacture of medicaments for human or veterinary use for the prevention or treatment of forms of oesophago-gastro­duodenal inflammation. Selective PPAR alpha and gamma agonists particularly suitable for the treatment of gastritis and relapses in a monotherapy regimen are selected from fibrates and glitazones.
PCT/IB2005/053121 2004-09-24 2005-09-22 Peroxisome proliferation receptor agonists, for the treatment of gastritis WO2006033081A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001825A ITMI20041825A1 (en) 2004-09-24 2004-09-24 RECEPTOR AGONISTS ACTIVATING THE PROLIFERATION OF PEROXYSOMES, USEFUL IN THE PREVENTION OR TREATMENT OF GASTRITIS
ITMI2004A001825 2004-09-24

Publications (2)

Publication Number Publication Date
WO2006033081A2 WO2006033081A2 (en) 2006-03-30
WO2006033081A3 true WO2006033081A3 (en) 2006-11-23

Family

ID=35462208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/053121 WO2006033081A2 (en) 2004-09-24 2005-09-22 Peroxisome proliferation receptor agonists, for the treatment of gastritis

Country Status (2)

Country Link
IT (1) ITMI20041825A1 (en)
WO (1) WO2006033081A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4976970A (en) * 1989-02-24 1990-12-11 Landy Wady N Pharmaceutical composition and method for treatment of digestive disorders
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
WO2003000301A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflammation
WO2003059294A2 (en) * 2002-01-14 2003-07-24 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
EP1380562A1 (en) * 2001-04-20 2004-01-14 Eisai Co., Ltd. Carboxylic acid derivative and salt thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4976970A (en) * 1989-02-24 1990-12-11 Landy Wady N Pharmaceutical composition and method for treatment of digestive disorders
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
EP1380562A1 (en) * 2001-04-20 2004-01-14 Eisai Co., Ltd. Carboxylic acid derivative and salt thereof
WO2003000301A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflammation
WO2003059294A2 (en) * 2002-01-14 2003-07-24 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERSTEIN L M ET AL: "EFFECTS OF MISCLERONE (CLOFIBRATE) ON DIMETHYLHYDRAZINE-INDUCED INTESTINAL CARCINOGENESIS IN RATS", ONCOLOGY, S. KARGER AG, BASEL, CH, vol. 39, September 1982 (1982-09-01), pages 331 - 335, XP002069292, ISSN: 0030-2414 *
LIPPMANN W ET AL: "CLOFIBRATE ANTI SECRETORY ANTI ULCER ACTIVITY IN THE RAT", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 28, no. 2, 1976, pages 165 - 166, XP008064017, ISSN: 0022-3573 *

Also Published As

Publication number Publication date
WO2006033081A2 (en) 2006-03-30
ITMI20041825A1 (en) 2004-12-24

Similar Documents

Publication Publication Date Title
MX2007005205A (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar.
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
HK1221958A1 (en) Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CL2008000691A1 (en) COMPOUNDS DERIVED FROM DIHIDRO AND TETRAHIDRO OXAZOLOPIRIMIDINONAS REPLACED; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CHICHOPHRENIA, EPILEPSY, BETWEEN OTHER DISEASES.
MX2009002903A (en) Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity.
CL2007000806A1 (en) COMPOUNDS DERIVED FROM REPLACED HETEROPENTACICLOS; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007002890A1 (en) Compounds derived from 2-pyridinecarboxamide, glucosinase activator; pharmaceutical composition; and use of the compound for the treatment of diabetes or obesity.
TW200800967A (en) Benzimidazole thiophene compounds
RS53056B (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-metoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
DE602006019825D1 (en) 1-SUBSTITUTED-7- (B-D-GLYCOPYRANOSYLOXY) (AZA) INDOL COMPOUND AND PHARMACEUTICALS CONTAINING THEM
ATE499932T1 (en) NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHODS
IL177366A0 (en) Substituted azetidine compounds as cyclooxygease-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
MX2010006206A (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases.
NO20091955L (en) Antiviral compositions and methods of use
NO20062088L (en) Pharmaceutical preparation comprising a selective I1-imidazoline receptor agonist and an angiotensin II receptor blocker
IL184048A0 (en) Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists
CL2007003198A1 (en) OPTIONALLY NITROGENATED DIARILIC COMPOUNDS, ANTAGONISTS OF OPIOID RECEIVERS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OBESITY.
WO2007095113A3 (en) Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
CL2008000906A1 (en) COMPOUNDS DERIVED FROM BENZIMIDAZOL; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMPOSITION PREPARATION PROCESS; AND USE IN THE TREATMENT OF A DISEASE MEDIATED BY THE ACTIVITY OF THE CANNABINOID 2 RECEIVER.
WO2006033081A3 (en) Peroxisome proliferation receptor agonists, for the treatment of gastritis
AU2003278814A8 (en) Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
NO20065471L (en) Use of IL-6 for the treatment or prevention of chemotherapy-induced neuropathy.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase